Reciprocal effects of antiretroviral drugs used to treat HIV infection on the fibroblast growth factor 21/β-Klotho System
Fecha de publicación2018
Gallego-Escuredo, José M.
Maroto, Alberto F.
Mateo, Gracia M.
Domingo, Joan C.
MetadatosMostrar el registro completo del ítem
Following antiretroviral therapy, HIV-infected patients show increased circulating levels of the antidiabetic hormone fibroblast growth factor 21 (FGF21). In contrast, the expression of the FGF21-obligatory coreceptor -Klotho (KLB) is reduced in target tissues. This situation is comparable to the FGF21 resistance status observed in obesity and type 2 diabetes. Here, we performed the first systematic study of the effects of distinct members of different antiretroviral drug classes on the FGF21/KLB system in human hepatic, adipose, and skeletal muscle cells. Most protease inhibitors and the nonnucleoside reverse transcriptase inhibitor efavirenz induced FGF21 gene expression. Neither nucleoside reverse transcriptase inhibitors nor the viral entry inhibitor maraviroc had any effect. Among the integrase inhibitors, elvitegravir significantly induced FGF21 expression, whereas raltegravir had minor effects only in adipose cells. In human hepatocytes and adipocytes, known target cells of FGF21 action, efavirenz, elvitegravir, and the lopinavir-ritonavir combination exerted inhibitory effects on KLB gene expression. Drug treatments that elicited FGF21 induction/KLB repression were those found to induce endoplasmic reticulum (ER) stress and oxidative stress. Notably, the pharmacological agents thapsigargin and tunicamycin, which induce these stress pathways, mimicked the effects of drug treatments. Moreover, pharmacological inhibitors of either ER or oxidative stress significantly impaired lopinavir–ritonavir-induced regulation of FGF21, but not KLB. In conclusion, the present in vitro screen study identifies the antiretroviral drugs that affect FGF21/KLB expression in human cells. The present results could have important implications for the management of comorbidities resulting from side effects of specific antiretroviral drugs for the treatment of HIV-infected patients.
Es parte deAntimicrobial Agents and Chemotherapy, 2018, vol. 62, núm. 6, p.1-13
Proyectos de investigación europeos
El ítem tiene asociados los siguientes ficheros de licencia:
Showing items related by title, author, creator and subject.
Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue Villarroya, Joan; Villarroya, Francesc; Gallego-Escuredo, José M.; Delgado‐Anglés, Alejando; Cairó, Montserrat; Moure, Ricardo; Mateo, Gracia M.; Domingo, Joan C.; Domingo, Pere; Giralt, Marta (Wiley Open Access, 2018)Fibroblast growth factor 21 (FGF21) has been proposed to be an antiaging hormone on the basis of experimental studies in rodent models. However, circulating FGF21 levels are increased with aging in rodents and humans. ...
Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome Díaz, Marta; Gallego-Escuredo, José M.; López-Bermejo, Abel; de Zegher, Francis; Villarroya, Francesc; Ibáñez, Lourdes (Hindawi, 2018)Background: Fetuin-A is a glycoprotein produced in the liver and related to metabolic syndrome; fetuin-A secretion is divergently regulated in different pathological conditions. In girls with polycystic ovary syndrome ...
Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells Morgado-Pascual, José L.; Rayego Mateos, Sandra; Valdivielso Revilla, José Manuel; Ortiz, Alberto; Egido, Jesús; Ruiz-Ortega, Marta (Hindawi Publishing Corporation, 2015)Chronic kidney disease is characterized by Vitamin D deficiency and activation of the renin-angiotensin-aldosterone system. Increasing data show that vitamin D receptor agonists (VDRAs) exert beneficial effects in renal ...